Holoclara gains Series A financing for worm-derived therapies
Holoclara has secured $16m in a Series A financing to advance new worm-derived therapies targeting allergic and autoimmune diseases.
Holoclara has secured $16m in a Series A financing to advance new worm-derived therapies targeting allergic and autoimmune diseases.
What's Your Reaction?
